{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T18:24:35Z","timestamp":1793903075414,"version":"4.8.0"},"reference-count":70,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,11,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chronic systemic inflammation contributes to the excess risk of atherosclerotic cardiovascular disease (ASCVD) in inflammatory rheumatic and musculoskeletal diseases (RMDs), raising the possibility that anti-inflammatory treatment may modify vascular risk. This review sought to critically address the mechanistic and clinical evidence for atheroprotection with colchicine and the commonly used conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) methotrexate, hydroxychloroquine, sulfasalazine and leflunomide. We performed a targeted narrative review of key experimental studies, randomized cardiovascular outcome trials, observational RMD cohorts and systematic reviews, prioritizing evidence directly relevant to ASCVD outcomes and cardiometabolic mechanisms. Colchicine has the strongest randomized evidence for reducing recurrent ASCVD events in patients with established coronary disease, with supportive observational data in gout. Methotrexate is associated with fewer cardiovascular events in rheumatoid arthritis (RA), whereas the CIRT trial was neutral in patients without inflammatory arthritis. Hydroxychloroquine has favourable lipid, glycaemic and antithrombotic effects and observational associations with lower cardiovascular risk in RA and systemic lupus erythematosus, but no definitive cardiovascular outcome trial. Evidence for sulfasalazine is limited and observational, and human data for leflunomide are conflicting. Cardiovascular benefit differs substantially between agents and is most convincing for colchicine in secondary prevention and for inflammation control with methotrexate in RA. Dedicated prospective trials in inflammatory RMD populations are needed before any csDMARD can be prescribed primarily for ASCVD prevention.<\/jats:p>","DOI":"10.1093\/rheumatology\/keag596","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T11:53:02Z","timestamp":1792756382000},"source":"Crossref","is-referenced-by-count":0,"title":["Cardioprotective mechanisms and efficacy of colchicine, methotrexate, hydroxychloroquine, sulfasalazine and leflunomide in inflammatory rheumatic and musculoskeletal diseases (RMDs)"],"prefix":"10.1093","volume":"65","author":[{"given":"Rabia","family":"Agca","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Reade Hospital , Amsterdam,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreen S","family":"Mohamed","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Reade Hospital , Amsterdam,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calin D","family":"Popa","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Sint Maartenskliniek , Nijmegen,","place":["The Netherlands"]},{"name":"Department of Rheumatology, Radboudumc , Nijmegen,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1625-9896","authenticated-orcid":false,"given":"Caroline","family":"van Durme","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Maastricht University Medical Centre+ , Maastricht,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3792-7718","authenticated-orcid":false,"given":"Harald E","family":"Vonkeman","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Medisch Spectrum Twente Hospital , Enschede,","place":["The Netherlands"]},{"name":"Department of Technology, Human and Institutional Behavior, University of Twente , Enschede,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suat","family":"Simsek","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine\/Endocrinology, Amsterdam University Medical Center , Amsterdam,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sjoerd","family":"Heslinga","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, St. Jansdal Hospital , Harderwijk,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1432-069X","authenticated-orcid":false,"given":"Sander I","family":"van Leuven","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Radboudumc , Nijmegen,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6274-1934","authenticated-orcid":false,"given":"Michael T","family":"Nurmohamed","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Reade Hospital , Amsterdam,","place":["The Netherlands"]},{"name":"Department of Rheumatology, Amsterdam University Medical Center , Amsterdam,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,23]]},"reference":[{"key":"2026110512271559600_keag596-B1","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nrcardio.2014.206","article-title":"Cardiorheumatology: cardiac involvement in systemic rheumatic disease","volume":"12","author":"Prasad","year":"2015","journal-title":"Nat Rev Cardiol"},{"key":"2026110512271559600_keag596-B2","doi-asserted-by":"crossref","first-page":"R85","DOI":"10.1186\/ar4527","article-title":"Cardiovascular disease is increased prior to onset of rheumatoid arthritis but not osteoarthritis: the population-based Nord-Tr\u00f8ndelag health study (HUNT)","volume":"16","author":"Pahau","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"2026110512271559600_keag596-B3","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1093\/rheumatology\/kead377","article-title":"Increased risk of cardiovascular disease preceding diagnosis of incident ANCA-associated vasculitis: a Danish nationwide study","volume":"63","author":"Nygaard","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"2026110512271559600_keag596-B4","doi-asserted-by":"crossref","first-page":"rkaf048","DOI":"10.1093\/rap\/rkaf048","article-title":"Atherosclerotic cardiovascular disease in systemic lupus erythematosus: from preclinical lupus to atherosclerotic plaque erosion","volume":"9","author":"van Leuven","year":"2025","journal-title":"Rheumatol Adv Pract"},{"key":"2026110512271559600_keag596-B5","doi-asserted-by":"crossref","first-page":"5205","DOI":"10.1093\/rheumatology\/keab204","article-title":"Patients with rheumatoid arthritis have impaired long-term outcomes after myocardial infarction: a nationwide case-control registry study","volume":"60","author":"Palom\u00e4ki","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2026110512271559600_keag596-B6","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1002\/1529-0131(200110)44:10<2331::AID-ART395>3.0.CO;2-I","article-title":"Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus","volume":"44","author":"Esdaile","year":"2001","journal-title":"Arthritis Rheum"},{"key":"2026110512271559600_keag596-B7","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1002\/art.21397","article-title":"Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis","volume":"52","author":"del Rinc\u00f3n","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2026110512271559600_keag596-B8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/rheumatology\/kem202","article-title":"Systemic inflammation as a risk factor for atherothrombosis","volume":"47","author":"van Leuven","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"2026110512271559600_keag596-B9","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41584-023-00969-7","article-title":"Shared inflammatory pathways of rheumatoid arthritis and atherosclerotic cardiovascular disease","volume":"19","author":"Weber","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"2026110512271559600_keag596-B10","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/s41569-024-01045-7","article-title":"Autoimmune diseases and atherosclerotic cardiovascular disease","volume":"21","author":"Porsch","year":"2024","journal-title":"Nat Rev Cardiol"},{"key":"2026110512271559600_keag596-B11","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0140-6736(23)00215-5","article-title":"Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials","volume":"401","author":"Ridker","year":"2023","journal-title":"Lancet"},{"key":"2026110512271559600_keag596-B12","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1161\/CIRCRESAHA.115.306656","article-title":"From C-Reactive Protein to Interleukin-6 to Interleukin-1: moving Upstream To Identify Novel Targets for Atheroprotection","volume":"118","author":"Ridker","year":"2016","journal-title":"Circ Res"},{"key":"2026110512271559600_keag596-B13","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"2026110512271559600_keag596-B14","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.semarthrit.2015.06.013","article-title":"Colchicine\u2014Update on mechanisms of action and therapeutic uses","volume":"45","author":"Leung","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"2026110512271559600_keag596-B15","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.clinthera.2014.07.017","article-title":"Mechanism of action of colchicine in the treatment of gout","volume":"36","author":"Dalbeth","year":"2014","journal-title":"Clin Ther"},{"key":"2026110512271559600_keag596-B16","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/ni.2550","article-title":"Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome","volume":"14","author":"Misawa","year":"2013","journal-title":"Nat Immunol"},{"key":"2026110512271559600_keag596-B17","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N Engl J Med"},{"key":"2026110512271559600_keag596-B18","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"key":"2026110512271559600_keag596-B19","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1161\/CIRCULATIONAHA.120.050771","article-title":"Colchicine in patients with acute coronary syndrome: the Australian COPS randomized clinical trial","volume":"142","author":"Tong","year":"2020","journal-title":"Circulation"},{"key":"2026110512271559600_keag596-B20","first-page":"618","article-title":"Colchicine in atherosclerotic cardiovascular disease","volume":"110","author":"Tucker","year":"2024","journal-title":"Heart"},{"key":"2026110512271559600_keag596-B21","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1093\/eurheartj\/ehab115","article-title":"Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials","volume":"42","author":"Fiolet","year":"2021","journal-title":"Eur Heart J"},{"key":"2026110512271559600_keag596-B22","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.jacc.2023.05.055","article-title":"Low-dose colchicine for secondary prevention of coronary artery disease","volume":"82","author":"Nelson","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026110512271559600_keag596-B23","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41584-021-00593-3","article-title":"Cardiovascular effects of approved drugs for rheumatoid arthritis","volume":"17","author":"Atzeni","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"2026110512271559600_keag596-B24","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.3899\/jrheum.111533","article-title":"Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout","volume":"39","author":"Crittenden","year":"2012","journal-title":"J Rheumatol"},{"key":"2026110512271559600_keag596-B25","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1136\/annrheumdis-2015-207984","article-title":"Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims","volume":"75","author":"Solomon","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2026110512271559600_keag596-B26","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/joim.70012","article-title":"Colchicine and the risk of major adverse cardiovascular events in patients with gout and type 2 diabetes: a nationwide cohort study","volume":"298","author":"Jeon","year":"2025","journal-title":"J Intern Med"},{"key":"2026110512271559600_keag596-B27","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1001\/jama.2022.11390","article-title":"Association between gout flare and subsequent cardiovascular events among patients with gout","volume":"328","author":"Cipolletta","year":"2022","journal-title":"JAMA"},{"key":"2026110512271559600_keag596-B28","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1093\/eurjpc\/zwaf513","article-title":"Ischemic cardiovascular risk with allopurinol and protective effect of colchicine in gout: a Dutch nationwide pharmaco-epidemiological study","volume":"33","author":"Peeters","year":"2026","journal-title":"Eur J Prev Cardiol"},{"key":"2026110512271559600_keag596-B29","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1016\/S2665-9913(24)00248-0","article-title":"Cardiovascular events in patients with gout initiating urate-lowering therapy with or without colchicine for flare prophylaxis: a retrospective new-user cohort study using linked primary care, hospitalisation, and mortality data","volume":"7","author":"Cipolletta","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"2026110512271559600_keag596-B30","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41584-020-0373-9","article-title":"Methotrexate and its mechanisms of action in inflammatory arthritis","volume":"16","author":"Cronstein","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"2026110512271559600_keag596-B31","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s41927-024-00381-y","article-title":"Methotrexate treatment strategies for rheumatoid arthritis: a scoping review on doses and administration routes","volume":"8","author":"Rubio-Romero","year":"2024","journal-title":"BMC Rheumatol"},{"key":"2026110512271559600_keag596-B32","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1172\/JCI116884","article-title":"The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation","volume":"92","author":"Cronstein","year":"1993","journal-title":"J Clin Invest"},{"key":"2026110512271559600_keag596-B33","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1136\/annrheumdis-2017-212537","article-title":"Methotrexate limits inflammation through an A20-dependent cross-tolerance mechanism","volume":"77","author":"Municio","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2026110512271559600_keag596-B34","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1136\/annrheumdis-2014-206305","article-title":"Methotrexate-mediated activation of an AMPK-CREB-dependent pathway: a novel mechanism for vascular protection in chronic systemic inflammation","volume":"75","author":"Thornton","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2026110512271559600_keag596-B35","doi-asserted-by":"crossref","first-page":"1209490","DOI":"10.3389\/fimmu.2023.1209490","article-title":"The actions of methotrexate on endothelial cells are dependent on the shear stress-induced regulation of one carbon metabolism","volume":"14","author":"Lang","year":"2023","journal-title":"Front Immunol"},{"key":"2026110512271559600_keag596-B36","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.amjcard.2011.06.054","article-title":"Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease","volume":"108","author":"Micha","year":"2011","journal-title":"Am J Cardiol"},{"key":"2026110512271559600_keag596-B37","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0140-6736(02)08213-2","article-title":"Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study","volume":"359","author":"Choi","year":"2002","journal-title":"Lancet"},{"key":"2026110512271559600_keag596-B38","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1136\/annrheumdis-2021-220125","article-title":"Investigating changes in disease activity as a mediator of cardiovascular risk reduction with methotrexate use in rheumatoid arthritis","volume":"80","author":"Johnson","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2026110512271559600_keag596-B39","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMoa1809798","article-title":"Low-dose methotrexate for the prevention of atherosclerotic events","volume":"380","author":"Ridker","year":"2019","journal-title":"N Engl J Med"},{"key":"2026110512271559600_keag596-B40","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1136\/ard.2008.093690","article-title":"Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research","volume":"68","author":"Salliot","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2026110512271559600_keag596-B41","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1177\/10600280231204969","article-title":"Hydroxychloroquine-Chloroquine, QT-prolongation, and major adverse cardiac events: a meta-analysis and scoping review","volume":"58","author":"Garcia","year":"2024","journal-title":"Ann Pharmacother"},{"key":"2026110512271559600_keag596-B42","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3892\/mmr.2025.13467","article-title":"Hydroxychloroquine: a double-edged sword","volume":"31","author":"Huo","year":"2025","journal-title":"Mol Med Rep"},{"key":"2026110512271559600_keag596-B43","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.5114\/amsad\/169982","article-title":"Hydroxychloroquine, QTc prolongation and risk of torsades de pointes","volume":"8","author":"Subhan","year":"2023","journal-title":"Arch Med Sci Atheroscler Dis"},{"key":"2026110512271559600_keag596-B44","first-page":"100243","article-title":"Hydroxychloroquine versus placebo in the treatment of non-hospitalised patients with COVID-19 (COPE-Coalition V): a double-blind, multicentre, randomised, controlled trial","volume":"11","author":"Avezum","year":"2022","journal-title":"Lancet Reg Health Am"},{"key":"2026110512271559600_keag596-B45","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40264-018-0689-4","article-title":"Cardiac complications attributed to chloroquine and hydroxychloroquine: a systematic review of the literature","volume":"41","author":"Chatre","year":"2018","journal-title":"Drug Saf"},{"key":"2026110512271559600_keag596-B46","doi-asserted-by":"crossref","first-page":"e698","DOI":"10.1016\/S2665-9913(20)30276-9","article-title":"Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study","volume":"2","author":"Lane","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"2026110512271559600_keag596-B47","doi-asserted-by":"crossref","first-page":"e70082","DOI":"10.1111\/bcpt.70082","article-title":"The role of hydroxychloroquine in the management of rheumatic disorders: a comprehensive review","volume":"137","author":"Ates","year":"2025","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2026110512271559600_keag596-B48","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2026110512271559600_keag596-B49","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.2147\/DDDT.S166893","article-title":"Chloroquine and hydroxychloroquine are associated with reduced cardiovascular risk: a systematic review and meta-analysis","volume":"12","author":"Liu","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"2026110512271559600_keag596-B50","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/acr.24850","article-title":"Hydroxychloroquine use and cardiovascular events among patients with systemic lupus erythematosus and rheumatoid arthritis: a nested case-control study","volume":"75","author":"Jorge","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026110512271559600_keag596-B51","doi-asserted-by":"publisher","first-page":"796","DOI":"10.3390\/jcm8060796","article-title":"Long-term hydroxychloroquine therapy and risk of coronary artery disease in patients with systemic lupus erythematosus","volume":"8","author":"Yang","year":"2019","journal-title":"J Clin Med"},{"key":"2026110512271559600_keag596-B52","first-page":"92","article-title":"Hydroxychloroquine for the prevention of recurrent cardiovascular events in myocardial infarction patients: rationale and design of the OXI trial","volume":"3","author":"Hartman","year":"2017","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026110512271559600_keag596-B53","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ijcard.2021.04.062","article-title":"Hydroxychloroquine reduces interleukin-6 levels after myocardial infarction: the randomized, double-blind, placebo-controlled OXI pilot trial","volume":"337","author":"Ulander","year":"2021","journal-title":"Int J Cardiol"},{"key":"2026110512271559600_keag596-B54","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1177\/0961203317722847","article-title":"Primary prevention of cardiovascular disease in patients with systemic lupus erythematosus: case series and literature review","volume":"26","author":"Fasano","year":"2017","journal-title":"Lupus"},{"key":"2026110512271559600_keag596-B55","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/FJC.0000000000001589","article-title":"Hydroxychloroquine and chloroquine-induced cardiac arrhythmias and sudden cardiac death in patients with systemic autoimmune rheumatic diseases: a systematic review and meta-analysis","volume":"84","author":"Nikolic","year":"2024","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026110512271559600_keag596-B56","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ipej.2020.10.002","article-title":"Hydroxychloroquine and QTc prolongation in patients with COVID-19: a systematic review and meta-analysis","volume":"21","author":"Agstam","year":"2021","journal-title":"Indian Pacing Electrophysiol J"},{"key":"2026110512271559600_keag596-B57","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1056\/NEJMoa2022926","article-title":"Effect of hydroxychloroquine in hospitalized patients with COVID-19","volume":"383","author":"Horby","year":"2020","journal-title":"N Engl J Med"},{"key":"2026110512271559600_keag596-B58","first-page":"100062","article-title":"Efficacy and safety of hydroxychloroquine as pre- and post-exposure prophylaxis and treatment of COVID-19: a systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials","volume":"2","author":"Martins-Filho","year":"2021","journal-title":"Lancet Reg Health Am"},{"key":"2026110512271559600_keag596-B59","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s10067-014-2769-x","article-title":"Sulfasalazine and its metabolites inhibit platelet function in patients with inflammatory arthritis","volume":"35","author":"MacMullan","year":"2016","journal-title":"Clin Rheumatol"},{"key":"2026110512271559600_keag596-B60","doi-asserted-by":"crossref","first-page":"R151","DOI":"10.1186\/ar2045","article-title":"Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study","volume":"8","author":"Van Halm","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"2026110512271559600_keag596-B61","doi-asserted-by":"crossref","first-page":"R30","DOI":"10.1186\/ar2383","article-title":"Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study","volume":"10","author":"Naranjo","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"2026110512271559600_keag596-B62","doi-asserted-by":"crossref","first-page":"e0326311","DOI":"10.1371\/journal.pone.0326311","article-title":"Risk of ischemic stroke associated with anti-rheumatic agents in patients with rheumatoid arthritis: a nationwide population-based case-control study","volume":"20","author":"Ahn","year":"2025","journal-title":"PLoS One"},{"key":"2026110512271559600_keag596-B63","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1042\/CS20180160","article-title":"A77 1726 (leflunomide) blocks and reverses cardiac hypertrophy and fibrosis in mice","volume":"132","author":"Ma","year":"2018","journal-title":"Clin Sci (Lond)"},{"key":"2026110512271559600_keag596-B64","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.7150\/ijbs.93465","article-title":"Antirheumatic drug leflunomide attenuates atherosclerosis by regulating lipid metabolism and endothelial dysfunction via DHODH\/AMPK signaling pathway","volume":"20","author":"Jiang","year":"2024","journal-title":"Int J Biol Sci"},{"key":"2026110512271559600_keag596-B65","doi-asserted-by":"crossref","first-page":"e23227","DOI":"10.1096\/fj.202301162R","article-title":"Leflunomide alleviates obesity via activation of the TAK1-AMPK pathway and induction of lipophagy","volume":"37","author":"Ji","year":"2023","journal-title":"The FASEB Journal."},{"key":"2026110512271559600_keag596-B66","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1136\/ard.61.6.567","article-title":"Leflunomide and hypertension","volume":"61","author":"Rozman","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"2026110512271559600_keag596-B67","doi-asserted-by":"crossref","first-page":"242","DOI":"10.2174\/1573397114666171227211048","article-title":"Onset of hypertension in leflunamide treated low socioeconomic rheumatoid arthritis patients: an unseen iceberg","volume":"15","author":"Ishaq","year":"2019","journal-title":"Curr Rheumatol Rev"},{"key":"2026110512271559600_keag596-B68","doi-asserted-by":"crossref","first-page":"113","DOI":"10.4078\/jrd.2024.0104","article-title":"Risk of acute myocardial infarction associated with anti-rheumatic agents in patients with rheumatoid arthritis: a nationwide population-based case-control study","volume":"32","author":"Ahn","year":"2025","journal-title":"J Rheum Dis"},{"key":"2026110512271559600_keag596-B69","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/art.22094","article-title":"Antirheumatic drug use and the risk of acute myocardial infarction","volume":"55","author":"Suissa","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2026110512271559600_keag596-B70","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1513\/AnnalsATS.202008-913OC","article-title":"Association between Leflunomide and Pulmonary Hypertension","volume":"18","author":"Lacoste-Palasset","year":"2021","journal-title":"Ann Am Thorac Soc"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keag596\/72452766\/keag596.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/11\/keag596\/72452766\/keag596.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/11\/keag596\/72452766\/keag596.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:27:28Z","timestamp":1793899648000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/doi\/10.1093\/rheumatology\/keag596\/8994473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":70,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11,4]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keag596","relation":{},"ISSN":["1462-0332"],"issn-type":[{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11]]},"published":{"date-parts":[[2026,10,23]]},"article-number":"keag596"}}